CR20200616A - Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión - Google Patents
Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropiónInfo
- Publication number
- CR20200616A CR20200616A CR20200616A CR20200616A CR20200616A CR 20200616 A CR20200616 A CR 20200616A CR 20200616 A CR20200616 A CR 20200616A CR 20200616 A CR20200616 A CR 20200616A CR 20200616 A CR20200616 A CR 20200616A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bupropion
- methods
- modulating
- plasma levels
- tetrabenazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>Esta divulgación se refiere a métodos que administran bupropión, como <em>S</em>bupropión o <em>R</em>-bupropión, junto con tetrabenazina, alfa-dihidrotetrabenazina o betadihidrotetrabenazina a un ser humano. También se describen formas de dosificación, sistemas de administración de fármacos y métodos relacionados con tetrabenazina, alfadihidrotetrabenazina o beta-dihidrotetrabenazina y bupropión, como <em>S</em>-bupropión o <em>R</em>bupropión</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862682998P | 2018-06-10 | 2018-06-10 | |
US201862683399P | 2018-06-11 | 2018-06-11 | |
PCT/US2019/036406 WO2019241162A1 (en) | 2018-06-10 | 2019-06-10 | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200616A true CR20200616A (es) | 2021-03-15 |
Family
ID=68843534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200616A CR20200616A (es) | 2018-06-10 | 2019-06-10 | Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP3790538A4 (es) |
JP (2) | JP2021529826A (es) |
KR (2) | KR20240034871A (es) |
CN (1) | CN112292121A (es) |
AU (2) | AU2019284477B2 (es) |
BR (1) | BR112020025064A2 (es) |
CA (1) | CA3101375A1 (es) |
CL (1) | CL2020003189A1 (es) |
CO (1) | CO2021000037A2 (es) |
CR (1) | CR20200616A (es) |
EC (1) | ECSP20082568A (es) |
IL (1) | IL279332A (es) |
MX (1) | MX2020013385A (es) |
NI (1) | NI202000095A (es) |
PE (1) | PE20210370A1 (es) |
SG (1) | SG11202011762VA (es) |
WO (1) | WO2019241162A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル(バルバドス)エスアールエル | 医薬組成物 |
US10105327B2 (en) * | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
US9707191B2 (en) * | 2013-11-05 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
IL288712B2 (en) * | 2015-03-06 | 2024-01-01 | Auspex Pharmaceuticals Inc | Methods for treating abnormal movement disorders |
WO2016210180A2 (en) * | 2015-06-23 | 2016-12-29 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for treating neurological diseases or disorders |
-
2019
- 2019-06-10 KR KR1020247007061A patent/KR20240034871A/ko not_active Application Discontinuation
- 2019-06-10 AU AU2019284477A patent/AU2019284477B2/en active Active
- 2019-06-10 BR BR112020025064-3A patent/BR112020025064A2/pt unknown
- 2019-06-10 EP EP19819780.8A patent/EP3790538A4/en active Pending
- 2019-06-10 CA CA3101375A patent/CA3101375A1/en active Pending
- 2019-06-10 CR CR20200616A patent/CR20200616A/es unknown
- 2019-06-10 PE PE2020001977A patent/PE20210370A1/es unknown
- 2019-06-10 CN CN201980038419.7A patent/CN112292121A/zh active Pending
- 2019-06-10 KR KR1020217000395A patent/KR20210018914A/ko not_active IP Right Cessation
- 2019-06-10 JP JP2021517931A patent/JP2021529826A/ja active Pending
- 2019-06-10 SG SG11202011762VA patent/SG11202011762VA/en unknown
- 2019-06-10 MX MX2020013385A patent/MX2020013385A/es unknown
- 2019-06-10 WO PCT/US2019/036406 patent/WO2019241162A1/en unknown
-
2020
- 2020-12-07 CL CL2020003189A patent/CL2020003189A1/es unknown
- 2020-12-09 IL IL279332A patent/IL279332A/en unknown
- 2020-12-09 NI NI202000095A patent/NI202000095A/es unknown
- 2020-12-18 EC ECSENADI202082568A patent/ECSP20082568A/es unknown
-
2021
- 2021-01-06 CO CONC2021/0000037A patent/CO2021000037A2/es unknown
-
2022
- 2022-11-09 AU AU2022268331A patent/AU2022268331A1/en active Pending
-
2024
- 2024-02-19 JP JP2024022880A patent/JP2024059744A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3790538A1 (en) | 2021-03-17 |
NI202000095A (es) | 2021-06-22 |
ECSP20082568A (es) | 2021-02-26 |
EP3790538A4 (en) | 2021-06-30 |
MX2020013385A (es) | 2021-05-27 |
KR20240034871A (ko) | 2024-03-14 |
PE20210370A1 (es) | 2021-02-26 |
JP2021529826A (ja) | 2021-11-04 |
AU2019284477A1 (en) | 2021-01-28 |
SG11202011762VA (en) | 2020-12-30 |
CL2020003189A1 (es) | 2021-05-28 |
AU2022268331A1 (en) | 2022-12-15 |
CA3101375A1 (en) | 2019-12-19 |
WO2019241162A1 (en) | 2019-12-19 |
AU2019284477B2 (en) | 2022-08-11 |
CN112292121A (zh) | 2021-01-29 |
BR112020025064A2 (pt) | 2021-03-23 |
JP2024059744A (ja) | 2024-05-01 |
IL279332A (en) | 2021-01-31 |
CO2021000037A2 (es) | 2021-01-18 |
KR20210018914A (ko) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
CA2956871C (en) | Compounds active towards bromodomains | |
PH12019500579A1 (en) | Pharmaceutical composition | |
PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EP3572070A4 (en) | RETARD ACTIVE SUBSTANCE RELEASE SYSTEM FOR ANALGETIC LOCAL STUNNING AND MANUFACTURING METHOD AND APPLICATION THEREOF | |
PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
MY181928A (en) | Sodium channel modulators for the treatment of pain and diabetes | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
MX2017003561A (es) | Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos. | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
MX2020005373A (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis. | |
TN2016000497A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
CR20200616A (es) | Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión | |
IN2013MU03370A (es) | ||
EP3760250A4 (en) | ADMINISTRATION DEVICE AND ADMINISTRATION SYSTEM FOR DRUG SOLUTION | |
MX2018010367A (es) | Titulacion de cebranopadol. |